Interaction between ferric carboxymaltose and denosumab causing severe hypocalcaemia and hypophosphataemia in a patient without chronic kidney disease.
Intern Med J
; 53(7): 1273-1276, 2023 07.
Article
en En
| MEDLINE
| ID: mdl-37384573
Coadministration of ferric carboxymaltose and denosumab may cause hypocalcaemia and hypophosphataemia; however, this interaction is not well-described in the literature and has typically been described in patients with chronic kidney disease (CKD). We present a case of this interaction in a patient without preexisting CKD. We suggest the use of alternative iron preparations and an interval of at least 4 weeks between administrations.
Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Hipofosfatemia
/
Anemia Ferropénica
/
Insuficiencia Renal Crónica
/
Hipocalcemia
Idioma:
En
Revista:
Intern Med J
Asunto de la revista:
MEDICINA INTERNA
Año:
2023
Tipo del documento:
Article